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) is present in the circulation and could con-
tribute to neurotoxicity if it crosses the brain capillary en-
dothelium, which comprises the blood–brain barrier (BBB)
in vivo. This study characterizes endothelial binding and

















binding to the brain microvascular endothelial cell mono-
layer was time dependent, polarized to the apical side, and



















was inhibited by anti-RAGE (receptor for advanced glycation
end products) antibody (63%) and by acetylated low density
lipoproteins (33%). Consistent with these data, transfected
cultured cells overexpressing RAGE or macrophage scavenger


























 was time and temperature de-
pendent, asymmetrical from the apical to basolateral side,




9 nM, and par-
tially sensitive to RAGE blockade (36%) but not to SR







 at the apical side of human BBB, and that RAGE















































 a heterogenous, 39–43 amino acid peptide,
is the main constituent of the senile plaques and cerebrovascu-





 is considered to be central to the pathology of AD be-
cause it may be neurotoxic—directly by inducing oxidant stress
and indirectly by activating microglia (3–5). It has been sug-
gested that the presence of pathological “chaperone” proteins
in brain and/or other predisposing factors is critical for the cy-












) is normally produced by different types of cells (6) and
is present in the circulation and cerebrospinal fluid (CSF) (7, 8)










 released from cells in
culture (6) and is the predominant form of cerebrovascular











 but is the major constitu-
ent of senile plaques (12). Recent quantitative analysis has


















 deposited in cerebral vasculature and















 could contribute to neurotoxicity if it crosses the
brain capillary endothelium, which comprises the blood–brain
barrier (BBB) in vivo (14). Transport of several peptides and
proteins through the brain capillary endothelium is possible
via receptor-mediated transcytosis (15–19). It has been sug-







 in rodents and nonhuman primates (14, 20–22).






 across the BBB in hu-
mans has not been studied, and it is not known whether spe-







human brain microvascular endothelial cells (HBMECs). In
addition, previously used in vivo techniques (14, 21–23) lack
the resolution to compare peptide binding and transport at the
apical versus basolateral side of brain endothelium. We hy-






 are present in
human brain capillaries, and that their endothelial cellular dis-
tribution may favor asymmetrical binding and transport of
peptide at the BBB. Thus, apical-to-basolateral transport may
allow circulating peptide to enter the brain and vessel wall
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which could be associated with its cytotoxic effects. In contrast,




from brain into blood that may ultimately decrease its tissue
levels. An in vitro model of human BBB (24, 25) was used to
test the above hypothesis and to characterize apical versus ba-
solateral HBMEC binding, endocytosis, and transcytosis of a






. The roles of




, including the recep-
tor for advanced glycation end products (RAGE) (4) and scav-

















-precursor amyloid protein (1–770) was custom synthesized at the









oxycarbonyl chemistry. Peptide was purified by reverse-phase high
pressure liquid chromatography (HPLC) using a C18 column (Vydac,
Hesperia, CA) and a linear gradient of 0–80% acetonitrile in 0.05%
trifluoroacetic acid (TFA). The final product was lyophilized and
characterized by analytical reverse phase HPLC, amino acid analysis,



























) was purchased from Sigma Chemical Co.















ersham Corp., Arlington Heights, IL) using Iodobeds (Pierce Chemi-
cal Co., Rockford, IL) following the manufacturer’s instructions. To






 oxidation at Met35 due to the radioiodin-
ation procedure, the peptide was subjected to reduction with 0.1 M
dithiothreitol for 6 h before purification. Labeled peptides were sepa-
rated from free iodine and oxidation derivatives by reverse-phase




m C4 narrow bore column (Vydac) and a 45-min
linear gradient from 0–70% acetonitrile. Protein elution was moni-
tored by absorbance at 280 nm and radioactivity evaluated in a
gamma counter (Beckman Instruments, Fullerton, CA). The result-























precipitable. Changes in the secondary structure due to the radioiodin-
ation procedure were evaluated by circular dichroism. Spectra in the
far ultraviolet range (260–190 nm) were recorded at 241C with a spec-
tropolarimeter (model J-720; Jasco Inc., Easton, MD) using a cell
path of 0.1 cm at a peptide concentration of 0.15 mg/ml in 20 mM
Tris, pH 7.4.
 
Isolation of human brain capillaries.
 
Human brain capillaries were
isolated from small fragments of cerebral cortex obtained from surgi-
cal resections from three adults with seizure disorder, as we recently
described (24). Portions with no pathologic lesions were used. Briefly,
brain specimens devoid of large blood vessels were homogenized in
DMEM containing 2% fetal bovine serum (FBS) using a Dounce ho-
mogenizer (VWR, San Diego, CA). The homogenate was centrifuged




 The pellets contain-
ing crude microvessels were further digested in a solution containing





lar capillaries were isolated by absorption to a column of glass beads




 95% as judged by a
trypan blue exclusion test.
 
Cultures and characterization of HBMECs.
 
The human brain mi-
crovessels were plated on rat-tail collagen-coated dishes or glass cov-
erslips and cultured in RPMI 1640–based medium with growth fac-
tors (24), FBS, NuSerum, endothelial cell growth supplement,




-glutamine (2 mM), sodium pyruvate (1 mM),
nonessential amino acids, vitamins, penicillin, and streptomycin (100









. The resulting HBMECs were positive for factor VIII–
 
related antigen, carbonic anhydrase IV, Ulex Europeus Agglutinin I,
and took up acetylated low density lipoprotein (AcLDL, ligand for





-glutamyl transpeptidase, indicating their brain ori-
gin. Detailed procedures regarding characterization of HBMECs
were as we previously reported (24).
In a separate set of experiments, cytospin slides of HBMECs
were prepared with a cytospin centrifuge (Shandon Lipshaw Corp.,
Pittsburgh, PA), and slides were rehydrated and stained with poly-
clonal rabbit antihuman anti-RAGE antibodies (4). Secondary per-
oxidase-labeled antibodies and development with diaminobenzidine
were used. Sections were lightly stained with hematoxylin. Fluores-
cent-labeled DiI-AcLDL was used to demonstrate the presence of









C, fixed with 2.5% glutaraldehyde in phosphate-buffered saline
(PBS), and viewed. Pictures were taken with a fluorescence micro-
scope (Nikon, Tokyo, Japan) as described (24).
 
In vitro model of the BBB.
 
Using the HBMECs, the BBB in vitro
model was constructed in inserts with collagen-fibronectin–coated
polycarbonate in Transwell membrane filters (Costar Corp., Cam-
bridge, MA) as we reported (25). A single monolayer of HBMECs
















l in the lower chamber. Analysis of the BBB by transmission elec-
tron microscopy (TEM) in 5-day-old primary cultures revealed flat
monolayers of endothelial cells covering the porous membrane com-
pletely. The apical surface of endothelial cells had neither microvilli
nor cytoplasmic processes. The cytoplasm of HBMECs contained
elongated nuclei, free ribosomes, few mitochondria, and endoplasmic
reticulum. Typical rod-shaped Weibel Palade bodies were observed
with a dark striated appearance. Bundles of intermediate filaments
were located under the basolateral cytoplasmic membrane, and mi-
crotubules were evenly distributed in the HBMEC cytoplasm. Occa-
sionally two or three HBMECs were overlaid on one another. Forma-
tion of gap and tight junctions were found between the thin cytoplasmic
processes of HBMECs. As we reported, the presence of astrocytes did
not positively affect the tightness of the HBMEC monolayer in this








 binding to HBMEC monolayers.
 
The HBMECs were pre-















C]inulin (10 nM) was
added to either the apical (upper) or basolateral (lower) chamber for









fects of internalization (endocytosis) and metabolism of ligand by




C. The inhibition of cell surface binding




C, and the tracer solution



















, HBMEC monolayers were first washed three
times in Hank’s balanced salt solution to remove unbound tracer, and
then exposed to 1 ml of acid wash solution (0.2 M acetic acid and 0.5 M










receptors participate in binding, the HBMEC monolayers were
treated for 30 min at 48C before and during [125I]sAb1–40 incubation
with different concentrations of anti-RAGE antibodies (4) or
AcLDL, a ligand for SR (5). To block the internalization of sAb1–40,
HBMEC monolayers were treated for 30 min at 378C before and dur-
ing [125I]sAb1–40 incubation with endocytic inhibitor, phenylarsine ox-
ide (PAO) at 20 mM (28–31). Although the exact molecular mecha-
nism for the inhibitory effect of PAO on endocytosis is not known, it
has been suggested that this trivalent arsenical forms a stable ring
with vicinal sulfhydryl groups, affects phosphoinositide metabolism,
and at higher concentrations reduces cellular energy stores, but at a
concentration used to inhibit endocytosis its other cellular actions are
minimized (28, 29). PAO inhibits internalization of several peptide
ligands (e.g., epidermal growth factor, insulin) (29), and at the BBB
receptor-mediated endocytosis of insulin (30) as well as endothelial
endocytosis of dynorphins (31).
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The HBMECs were detached from the membrane insert using
0.1% EDTA in Hank’s solution. For degradation studies, the HBMECs
were incubated with [125I]sAb1–40 (3.5 nM) within 30 min at 378C. Ali-
quots of the assay buffer and endothelial cell homogenates were pre-
pared for analysis of total and TCA (12%)-precipitable [125I] radio-
activities to determine the fraction of [125I]sAb1–40 that was not
degraded. Uptake and metabolism of sAb1–40 by HBMECs were also
studied in several assay buffer and HBMEC samples with HPLC to
corroborate the results of TCA precipitation analysis. Prior to extrac-
tion and HPLC fractionation, the HBMECs were exposed to acid
wash solution (0.2 M acetic acid and 0.5 M NaCl for 6 min) to remove
surface-bound sAb1–40. HBMEC samples were then prepared by hy-
potonic lysis as reported (32). Briefly, HBMECs were homogenized
in water containing protease inhibitors (0.5 mM phenylmethylsulfo-
nyl fluoride, 1 mg/ml leupeptin, and 1 mM p-amino-benzamidine) and
centrifuged at 100,000 g for 1 h at 48C. The supernatant was then ly-
ophilized. The resulting material was dissolved in 0.1% TFA in water,
pH 2.1, before injection onto the HPLC column. The aliquots of assay
buffer samples from upper and lower chamber were diluted in 0.1%
TFA in water, pH 2.1, before injection onto the HPLC column. Sepa-
ration was achieved using a C4 column (Vydac, The Separation
Group) with a 30-min linear gradient of 25–83% acetonitrile in 0.1%
TFA at a flow rate of 1 ml/min. Under these conditions, the sAb1–40
standard eluted at 15.5 min. Column eluants were monitored at 214
nm. The eluted fractions were collected and counted using a gamma
counter (Beckman Instruments). Protein content of the BMEC
monolayers was determined by the Lowry method (33).
All measurements were done in triplicate. [125I] and [14C] radioac-
tivities were determined in a gamma counter (model 4000; Beckman
Instruments) and a liquid scintillation spectrometer (model LS-7500;
Beckman Instruments), respectively. Parameters governing the bind-
ing of [125I]sAb1–40 to BMECs were estimated by nonlinear least
squares regression using the software program SAAM II (University
of Washington, Seattle, WA), with initial parameter estimates deter-
mined by Scatchard analysis (34).
sAb1–40 transendothelial transport across HBMEC monolayers.
These experiments were carried out at 378C. Samples (0.2 ml) were
removed from both the apical (upper) and basolateral (lower) cham-
bers to determine the extent of tracer passage across the BMEC
monolayer. To control for nonspecific 125I-sAb1–40 leakage, 14C-inulin
leakage across monolayers was determined simultaneously in all ex-
periments. The amount of intact sAb transcytosed across the HBMECs
was expressed as the percent of the radioactivity dose of 125I-sAb1–40
transported from the apical to basolateral side and corrected for the
nonspecific leakage as (16): 125I cpm 3 TCA-precipitable radioactiv-
ity in sample 2 [125I cpm 3 TCA-precipitable radioactivity in dose 3
k 3 (14C dpm in sample/14C dpm in dose)], where sample and dose
denote the radioactivities of intact sAb in the lower (basolateral) and
upper (apical) chamber, respectively, when the radiolabeled peptide
was added to the upper chamber; k 5 (molecular weight of inulin)1/2/
(molecular weight of sAb1–40)1/2 to correct for the nonspecific leakage
and the differences in inulin and sAb1–40 diffusion across the coated
membrane. When basolateral-to-apical transport of sAb was studied,
the same formula was applied, but in this case the dose represented
the radioactivity of intact sAb added to the basolateral chamber,
and the sample represented the radioactivity of sAb in the upper
chamber. Since transendothelial basolateral-to-apical transport of
sAb corrected for nonspecific leakage was undetectable, the trans-
port parameters described below were determined only for apical-to-
basolateral transport. Degradation of sAb1–40 following transport
across the HBMECs was studied in several assay buffer samples from
the apical and basolateral chambers with HPLC (31) using the procedure
as described above. The HPLC analysis was performed to corrobo-
rate the results of TCA precipitation analysis. The permeability-sur-
face area (PS) product for sAb1–40 in the apical-to-basolateral direc-
tion was calculated using the equation PS 5 X/(A 3 t 3 CD) where X
and CD are concentrations of 125I-sAb1–40 in lower and upper cham-
ber, respectively, t is the time of exposure, and A is the surface area,
as reported (16). The inhibition of 125I-sAb1–40 transport in apical-to-
basolateral direction was studied in the presence of unlabeled sAb1–40
(0.5–150 nM), 150 nM sAb40–1 and different concentrations of anti-
RAGE antibody (5–40 mg/ml) and AcLDL (50–800 mg/ml). The
transendothelial apical-to-basolateral influx, Jin, of 125I-sAb1–40 in the
presence of various concentrations of unlabeled peptide in the upper
chamber, C, was calculated as (16, 19): Jin 5 PS 3 C 3 q, where q is
the amount of protein (in mg) per number of cells in HBMEC mono-
layers occupying the surface area A available for transendothelial
transport. Kinetic transport Michaelis–Menten parameters, Km
(Michaelis affinity constant) and Vmax (maximal transport capacity)
for intact sAb1–40 were calculated with a nonlinear regression analysis
using SAAM II program as reported (19).
Radioligand binding and internalization studies in transfected
cultured cells overexpressing RAGE or macrophage SR type A. For
the RAGE overexpression system, Chinese hamster ovary (CHO)
cells were transiently transfected with pcDNA3/RAGE (human
RAGE) using lipofectamine (GIBCO/BRL, Grand Island, NY). RAGE
expression in these cells was characterized by immunoblotting and
immunocytochemistry as described (35). For the SR overexpression
system, Bowes cells stably transfected to overexpress the macrophage
SR type A, characterized as previously described (36), were em-
ployed. In brief, cultures were grown to confluence (z 106 cells/well),
medium was aspirated, cells were washed with Hank’s balanced salt
solution over 10 min (5 min/wash) at room temperature, and then
binding buffer (minimal essential medium containing fatty acid-free
bovine serum albumin 0.1%) was added (50 ml/well). For radioligand
binding studies, cultures were briefly (20 min) pretreated with para-
formaldehyde (2%) after the washing procedure to prevent internal-
ization of bound ligand as described previously (37). Wells were incu-
bated with 125I-sAb1–40 alone or in the presence of an 100-fold molar
excess of unlabeled sAb1–40 for 120 min at 378C. This incubation time
was required for apparent maximal binding at the lowest tracer con-
centrations. After the incubation period, wells were rapidly washed
four times in ice-cold binding buffer over 30 s (this time period was
sufficiently rapid to prevent significant dissociation of bound ligand
[, 5–10%]). Cell-bound radioactivity was eluted by incubating wells
for 5 min at 378C with PBS containing heparin (10 mg/ml) or with sa-
line containing NP-40 (1%) for 5 min at 378C. Specific binding, the
difference between total binding (that observed with 125I-sAb1–40
alone) and nonspecific binding (that observed with 125I-sAb1–40 in the
presence of an 100-fold excess of unlabeled sAb1–40) was analyzed by
the method of Klotz and Hunston (37), using nonlinear least squares
analysis (Enzfitter). Specific binding according to these methods was
identical following elution with heparin or NP-40.
For internalization studies, similar methodology was employed,
except cells were not exposed to paraformaldehyde. The experiment
was also performed at 378C for 1 min. Following washing to remove
unbound tracer, cultures were sequentially exposed to heparin-con-
taining buffer (as above), to elute surface-bound radioactivity, and
then NP-40, to elute cell-associated radioactivity not accessible to
heparin (i.e., internalized ligand). For morphologic studies, cultures
were incubated with nonradioactive sAb1–40 according to the same
protocol described above for tracking internalized ligand. Then, cul-
tures were fixed in paraformaldehyde (2%) with/without NP-40
(0.1%) and studied for localization of Ab by immunocytochemistry
using anti-Ab1–40 immunoglobulin G (IgG) as the primary antibody
(QCB, Hopkinton, MA) and affinity purified fluorescein isothiocyan-
ate-labeled goat anti–rabbit IgG as the secondary antibody (Sigma
Chemical Co.).
Results
The analysis of HBMECs by TEM in 5-day-old primary cul-
tures revealed a flat and continuous monolayer of cells bound
by the tight junctions (Fig. 1 A). At 378C, the specific binding
of sAb1–40 was found only at the apical side and was absent
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from the basolateral side (Fig. 1 B). The total binding of 125I-
sAb1–40 (0.5 nM) to the apical cell surface was rapid and pro-
gressively increased within the first 5 min. A steady-state level
was reached between 5 and 60 min. The majority of binding
(75–80%) was resistant to removal by acid wash, indicating in-
corporation into apical membrane or endocytosis at physiolog-
ical temperature. The temperature dependence of sAb1–40
binding and internalization was evident (Fig. 1 C). At 48C, the
total binding at the apical side was significantly reduced, asso-
ciated with a decrease in acid-resistant binding (i.e., intracellu-
lar binding). There was a minimal degree of metabolism or
degradation of 125I-sAb1–40 by HBMECs at 378C (Fig. 1 D); af-
ter 30 min and 60 min (data not shown) . 94% of peptide
(corrected for the counts removed by an acid wash) remained
intact in endothelial cells as confirmed by the HPLC analysis
of HBMEC lysates following removal of cell surface–bound
125I-sAb1–40 by an acid wash. Similar results were obtained
when trypsin:proteinase K:EDTA solution was used to re-
move cell surface–bound ligand (data not shown). Binding of
125I-sAb1–40 to the apical side was saturable in the presence of
increasing concentrations of unlabeled sAb1–40 (Fig. 1 E, inset).
Specificity of sAb1–40 binding was reflected by the minimal in-
fluence of 150 nM reverse sAb40–1 peptide. Scatchard analysis
of the binding data at 48C indicated the presence of two inde-
pendent sAb1–40 binding sites (Fig. 1 E, main graph). The non-
linear regression analysis indicated a high-affinity binding site
with a dissociation constant K1d of 7.861.2 nM (estimate6SD)
and binding maximum (B1max) of 3.7560.52 pmol/mg of pro-
tein. The second class of binding sites was of lower affinity (K2d
of 52.866.2 nM) and higher capacity (B1max of 15.7560.25
pmol/mg of protein). As illustrated in Fig. 1 F, the amount of
sAb1–40 that was internalized by HBMECs (i.e., resistant to re-
Figure 1. (A) TEM of HBMEC 
monolayer showing continuous en-
dothelial cells bound to each other 
with tight junctional complexes (ar-
row); ***supporting membrane 
(319,000). (B) Distribution of sAb1–40 
receptors in HBMEC monolayers. 
125I-sAb1–40 (0.5 nM) was added to 
either apical or basolateral compart-
ment of HBMECs grown on sup-
porting membrane. Total (solid cir-
cles) and acid-resistant (open 
circles) binding at 378C at the apical 
side of the HBMEC. Binding of 125I-
sAb1–40 was undetectable at the ba-
solateral side (solid squares). (C) At 
48C, total binding (solid circles) at 
the apical side was significantly re-
duced associated with a decrease in 
acid-resistant binding (open cir-
cles). (D) The HPLC profile of HB-
MEC lysates prepared following ex-
posure to 125I-sAb1–40 (3.5 nM) for 
30 min at 378C show mainly (94.1%) 
intact peptide in acid-resistant frac-
tion following acid wash (main 
graph). An HPLC profile of intact 
125I-sAb1–40 was shown as a control 
(inset). (E) Saturable binding of 125I-
sAb1–40 to the apical surface at 48C 
in the presence of increasing con-
centrations of sAb1–40 was not af-
fected by the reverse peptide, sAb40–1 
(inset). Scatchard analysis (main 
graph) showed two independent 
classes of binding sites. Nonlinear 
least squares regression analysis was 
used to estimate the dissociation 
constant (K1d) and binding capacity 
(B1max) of the high affinity site as 
7.861.2 nM and 3.7560.52 pmol/mg 
of protein (estimate6SD). For the 
low-affinity, high-capacity sites, K2d was estimated at 52.866.2 nM, and B2max 5 15.7560.25 pmol/mg of protein. (F) Effect of 20 mM PAO on the 
internalization of 125I-sAb1–40. The total amount of 125I-sAb1–40 bound to the HBMECs, as well as the extracellular (acid wash removable) and in-
tracellular (acid wash resistant) components were examined following a 30-min incubation at 378C. *P , 0.05, for total and acid resistant 125I-
sAb1–40, nsnonsignificant for acid removable 125I-sAb1–40 in PAO-treated compared with respective controls, by Student’s t test. (B, C, E, and F) 
The values are mean6SD of three monolayers determined in triplicate; mgp 5 mg of protein.
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moval by acid wash) was significantly reduced by 20 mM PAO,
an endocytic inhibitor. In all experiments, the HBMEC uptake
of simultaneously exposed 14C-inulin was barely above the
background level, indicating the absence of a nonspecific leak
into the cells and minimal entrapping of the tracer in the me-
dium between the cells at the sites of junctional complexes.
Transendothelial transport of sAb1–40 was asymmetrical in
the apical-to-basolateral direction. At 378C, transport from the
upper to the lower chamber was significantly higher for intact
125I-sAb1–40 (TCA-precipitable) than for 14C-inulin, an extra-
cellular space marker transported across the monolayer by a
nonspecific diffusion (leakage) through the intercellular pores
or junctions (Fig. 2 A). In contrast, basolateral-to-apical trans-
port of sAb1–40 was comparable to inulin. Apical-to-basolateral
transport of sAb1–40 across the endothelial monolayer cor-
rected for the nonspecific leakage (inulin transport) was time
dependent and sensitive to reduced temperature (Fig. 2 B).
When corrected for the nonspecific leakage, basolateral-to-api-
cal transport of 125I-sAb1–40 was undetectable. Figure 2 C illus-
trates dose-dependent inhibition of 125I-sAb1–40 PS product
(corrected for the nonspecific leakage) by increasing concen-
trations of unlabeled sAb1–40 in the apical (upper) chamber.
The specificity of transport was shown by the lack of effect of
sAb40–1. The Michaelis–Menten analysis revealed the Km of
4569 nM and Vmax of 2.1060.35 pmol/min/mg of protein (Fig.
2 D).
Figure 3 A indicates that anti-RAGE antibody (20 mg/ml)
inhibits by about 63% the binding of 125I-sAb1–40 to the apical
side of the BBB. AcLDL at a maximal inhibitory concentra-
tion of 800 mg/ml was able to produce about 32% inhibition of
125I-sAb1–40 binding, and a further increase in the AcLDL con-
centration did not result in a greater decrease of 125I-sAb1–40
binding (data not shown). Maximal inhibition of 125I-sAb1–40
binding by anti-RAGE 1 AcLDL was 95.6%. As shown by
the inset, there was a progressive dose-dependent inhibition of
125I-sAb1–40 binding by anti-RAGE at 48C in the presence of a
maximal inhibitory concentration of AcLDL; the maximal in-
hibition with anti-RAGE was achieved at 20 mg/ml. Figure 3 B
shows that at 378C, anti-RAGE (20 mg/ml) inhibits apical-
to-basolateral transport of 125I-sAb1–40 by about 36%, and fur-
ther increase in the anti-RAGE concentration did not produce
greater inhibition (Fig. 3 B, inset). The addition of AcLDL at
maximal concentrations did not affect transcytosis of 125I-sAb1–40.
The expression of RAGE and SR in the present HBMEC sys-
tem was shown by immunocytochemistry (RAGE) and uptake
of endothelial SR ligand, fluorescent DiI-AcLDL (Fig. 3, C
and D). We previously reported that glycoprotein 330, gp330/
megalin, is expressed at the BBB, but does not participate in
binding and transport of free Ab1–40 (38). This has been con-
firmed in the present BMEC model and the expression of
gp330/megalin shown by immunocytochemistry with mouse
monoclonal 1H12 anti–human anti-gp330 antibodies, kindly
provided by R. McCluskey, Harvard University (data not
shown; Stins et al., unpublished observations). Figure 3 E illus-
trates that unlabeled LDL (low density lipoproteins) at con-
centrations as high as 800 mg/ml does not affect the uptake of
125I-AcLDL (1 nM) exposed for 1 h to the apical side of the
HBMEC monolayers, indicating that LDL receptor does not
participate in uptake of AcLDL, as shown previously (39, 40).
Our results with cultured HBMECs led us to analyze di-
rectly the potential involvement of RAGE and SR in cellular
handling of sAb1–40 using transfected cell systems in which the
Figure 2. Asymmetrical transendothelial 
transport of sAb1–40 across HBMEC 
monolayers. (A) 125I-sAb1–40 (0.5 nM) and 
14C-inulin (10 nM) were added to either 
apical or basolateral compartment of 
HBMEC for 30 min at 378C. Ordinate, 
percent of the radioactivity dose of 125I-
sAb1–40 (open bars) and 14C-inulin (pat-
terned bars) transported from either 
apical-to-basolateral (left), or basolateral-
to-apical (right) compartment. *P , 
0.05, nsnonsignificant for 125I-sAb1–40 and 
14C-inulin, by Student’s t test. (B) Time 
and temperature dependence of apical-
to-basolateral 125I-sAb1–40 transport cor-
rected for the nonspecific leakage of trac-
ers (solid points at 378C; open points at 
48C). Basolateral-to-apical transport 
(open squares) was undetectable at 378C. 
(C) Inhibition of the permeability-surface 
area (PS) product of 125I-sAb1–40 (trans-
port in apical-to-basolateral direction) 
by increasing concentrations of unlabeled 
sAb1–40 at the apical side, and lack of the 
effect of sAb40–1. (D) Apical-to-basolat-
eral saturable influx (Jin) of 125I-sAb1–40 
determined at 378C in the presence of in-
creasing concentrations of unlabeled 
sAb1–40. (B, C, and D) The values for in-
tact 125I-sAb1–40 were corrected for the diffusion across intercellular junctions (nonspecific leakage of tracer) by subtracting corresponding values 
for 14C-inulin. Values are mean6SD of three monolayers determined in triplicate; mgp 5 mg of protein.
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Ab-cellular interactions were mediated principally by the lat-
ter two receptors. CHO cells transiently transfected with
pcDNA3/RAGE displayed expression of RAGE, by immuno-
blotting and immunocytochemistry, compared with mock-
transfected controls (Fig. 4 A, BI–II). Transiently transfected
CHO cells demonstrated specific binding of 125I-sAb1–40 com-
pared with mock-transfected controls (Fig. 4 C). Cells were
briefly exposed to paraformaldehyde (2%) to prevent inter-
nalization during binding assays performed at 378C, and
RAGE-dependent 125I-sAb1–40 binding was dose-dependent
with Kd . 72.0642.1 nM. Cell-associated radioactivity was re-
stricted to the surface, as shown by complete elution of specifi-
cally bound 125I-sAb1–40 with heparin under these conditions
(Fig. 4 D, fixed cell). If heparin solution was followed by disso-
lution of the cells in NP-40 containing buffer, no additional
specifically bound tracer was recovered using paraformaldehyde-
treated cells. In contrast, when experiments were performed at
378C without paraformaldehyde, endocytosis of cell-associated
125I-sAb1–40 resulted in two pools of ligand (Fig. 4 D, unfixed
cell); most ligand was still on the cell surface (z 82–83% by 3
h). However, a component of specifically bound ligand was
present in a heparin-resistant, NP-40–elutable pool (z 17–
18%). Immunocytochemistry was performed using an anti-
body specific for Ab1–40. To visualize internalized ligand, fol-
lowing the incubation period at 378C, cell surface sAb1–40 was
eluted with heparin-containing buffer. The absence of surface-
associated ligand following heparin treatment of RAGE-trans-
fected CHO cells was confirmed by immunocytochemistry of
nonpermeabilized cells (Fig. 4 E, I). Next, after heparin elu-
tion, cultures were permeabilized with NP-40, and the pres-
ence of a pool of sAb1–40 present in a granular pattern was ob-
served (Fig. 4 E, II). Thus, the latter sAb1–40 represented inter-
nalized ligand.
Similar radioligand and internalization studies were per-
formed using stably transfected Bowes cells overexpressing SR
type A. This scavenger receptor was selected for our studies in
view of its identification in brain microvasculature (39). Sur-
face binding was evaluated at 378C using cells briefly exposed
Figure 3. (A) Binding of 125I-sAb1–40 
to the apical side of the BBB in 
the presence of anti-RAGE and 
AcLDL (SR ligand). The HBMEC 
monolayers were treated for 30 min 
at 48C before and during [125I]-
sAb1–40 incubation with anti-RAGE 
and AcLDL. The main graph shows 
maximal inhibitions of [125I]-sAb1–40 
binding by anti-RAGE (20 mg/ml; 
horizontally patterned bar) and 
AcLDL (800 mg/ml; black bar) sepa-
rately, or together (gray bar); con-
trol uptake (open bar) and no effect 
of normal rabbit IgG (vertically pat-
terned bar). The inset illustrates the 
effect of increasing anti-RAGE con-
centration on [125I]sAb1–40 binding in 
the presence of maximal inhibitory 
concentration of AcLDL (800 mg/
ml). (B) Apical-to-basolateral 
transendothelial transport of 125I-
sAb1–40 corrected for nonspecific 
leakage of tracers in the presence of 
anti-RAGE and AcLDL. The HB-
MEC monolayers were treated for 
30 min at 378C before and during 
[125I]sAb1–40 incubation with anti-
RAGE and AcLDL. The main graph 
shows inhibition of [125I]sAb1–40 
transport by anti-RAGE (20 mg/ml; 
horizontally patterned bar) in com-
parison with control transport val-
ues (open bar), and no effect of rab-
bit IgG (vertically patterned bar). 
The lack of AcLDL effect either 
alone (800 mg/ml; patterned bar) or 
together with anti-RAGE (black 
bar) is also shown. The inset illus-
trates the effect of increasing anti-RAGE concentration on [125I]sAb1–40 transport. *P , 0.05, nsnonsignificant for [125I]sAb1–40 in the absence and 
presence of anti-RAGE, AcLDL, or anti-RAGE 1 AcLDL, by Student’s t test. (C) Immunoctytochemical detection of RAGE in HBMEC with 
anti-RAGE (1:200) antibody (left) and negative control (right, omission of primary antibody). (D) Uptake of fluorescent DiI-AcLDL (10 mg/ml) 
by HBMEC. (E) Uptake of 125I-AcLDL (1 nM) by HBMEC (open bar, control) at 378C and exposed for 1 h to the apical side of the HBMEC 
monolyears is not affected with 800 mg/ml unlabeled LDL (horizontally patterned bar). (A, B, and E) Control values were arbitrarily set as 
100%. (C and D) The bar is 5 mm. Values are means6SD of three monolayers determined in triplicate.
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to paraformaldhyde as described above. Compared with mock-
transfected controls, SR-transfected Bowes cells displayed
specific binding of 125I-sAb1–40. Binding was dose dependent,
displaying Kd . 101.7632.9 nM (Fig. 5 A). Pretreatment of
cultures with paraformaldehyde prevented internalization of
cell-bound 125I-sAb1–40, as complete elution of specifically
bound ligand was observed with heparin (Fig. 5 B, fixed cell).
Under these conditions, no increments in specifically bound 125I-
sAb1–40 was observed following NP-40 elution. In contrast, ex-
periments with live (i.e., unfixed) cells and 125I-sAb1–40 per-
formed at 378C demonstrated the appearance of a sizeable pool
of heparin-resistant cell-associated tracer. Following heparin
elution of cell surface–bound tracer, NP-40 elution recovered
an additional z 70% of total specifically cell-associated radio-
activity. Immunocytochemistry was used to confirm the pres-
ence of internalized Ab. Following incubation of cultures with
sAb1–40 at 378C, cultures were exposed to heparin to elute sur-
face-bound ligand (Fig. 5 C, I). Subsequent permeabilization
of these cells with NP-40 resulted in the appearance of a pool
of sAb1–40 in a granular pattern (Fig. 5 C, II) which represented
internalized ligand.
Discussion
These studies indicate that sAb1–40 is bound and internalized at
the apical side of the HBMECs cultured on membrane inserts
Figure 4. Interaction of RAGE with sAb1–40: 
studies on RAGE-transfected CHO cells. 
(A) Immunoblotting. CHO cells were tran-
siently transfected with pcDNA3/RAGE 
(lane 2) or pcDNA3 alone (lane 1), lysates 
were prepared, and subjected to reduced 
SDS-PAGE (10%; 50 mg total protein/
lane) followed by immunoblotting with 
rabbit anti-human RAGE IgG (4 mg/ml 
[47]) and visualization of primary antibody 
with peroxidase-conjugated anti-rabbit IgG 
and the ECL system. (BI–BII) Immuno-
cytochemical visualization of RAGE. 
RAGE-transfected (BI) and mock-trans-
fected (BII) CHO cells were fixed in para-
formaldehyde (2%) alone and then incu-
bated with rabbit anti-RAGE IgG (6.5 mg/
ml) followed by FITC-conjugated goat 
anti–rabbit IgG. Magnification, 400. (C) 
Dose dependence of 125I-sAb1–40 binding. 
RAGE-transfected CHO cells were incu-
bated with the indicated concentrations of 
125I-sAb1–40 alone or in the presence of 100-
fold excess unlabeled ligand. Specific bind-
ing (total minus nonspecific binding) is 
plotted versus free (assumed to be the 
same as added) ligand. Binding was ana-
lyzed by nonlinear least squares. (D) Iden-
tification of cell surface-associated and in-
ternalized 125I-sAb1–40. RAGE-transfected 
CHO cells were either briefly treated with 
paraformaldehyde (2%; fixed cells) or in-
cubated in buffer alone (unfixed cells), fol-
lowed by exposure to 125I-sAb1–40 (54 nM) 
alone or in the presence of 100-fold excess 
unlabeled sAb1–40 for 2 h at 378C. Cultures 
were then washed, and exposed to heparin-
containing elution buffer (heparin) fol-
lowed by NP-40–containing elution buffer 
(NP-40). Specifically bound ligand under 
each condition is shown as a percentage of 
total specific binding. (EI–EII) Visualiza-
tion of cell-associated sAb1–40. RAGE-
transfected CHO cells were incubated with 
sAb1–40 at 378C. Cells were exposed to hep-
arin containing buffer to elute surface 
bound Ab (EI), or were exposed to hep-
arin followed by permeabilization with NP-
40 containing buffer (EII). Immunocy-
tochemistry to visualize Ab was performed 
as described in the text.
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by two specific acceptor sites. The binding constant of the
high-affinity sAb1–40 BBB sites (Kd 5 7.8 nM) was comparable
to Kd’s determined for human brain capillary receptors for
peptides such as leptin, transferrin, insulin, and insulin-like
growth factors (41). The binding maximum of the high-affinity
sAb1–40 BBB sites was at least an order of magnitude higher
than for the peptide hormones. The second class of lower af-
finity sites (Kd 5 52.8 nM) exhibited 4.2-fold greater binding
capacity than the high-affinity sites. The inhibition studies in-
dicated that RAGE and SR are receptors involved in binding
of free sAb1–40 at the apical side of the BBB. In contrast, the
BBB binding and transport of Ab complexed to apolipopro-
tein J (apoJ) is mediated via gp330/megalin (38), and this
receptor does not recognize the free form of peptide. The
specific transport system mediating asymmetrical apical-
to-basolateral transcytosis of free sAb1–40 was also found. The
affinity constant of human BBB sAb1–40 transporters (45 nM)
compares well with the initially reported Km of 42 nM for satu-
rable sAb1–40 BBB transport in vivo in rodents (20). Transport
was partially sensitive to RAGE blockade but also involved a
RAGE-independent component, possibly a novel cellular
“chaperone” transporter protein for sAb.
The lack of specific sAb1–40 binding at the basolateral side
of the HBMEC monolayer suggests that all specific high-affin-
ity binding sites at normal human BBB may be located at the
apical side, similar as for insulin (30). The polarity of the BBB
in present HBMEC model (24, 25) seems to be preserved (42),
as indicated by cellular distribution of the A amino acid trans-
porter and enrichment of the sodium pump at the basolateral
side (Stins, M., S. Jovanovic, J.B. Mackic, K.S. Kim, and B.V.
Zlokovic, unpublished observations). Previous work on in
vitro BBB models indicated that several peptides (e.g., vaso-
pressin, atrial natriuretic peptide) in contrast to sAb1–40 are
taken up by specific mechanisms only at the basolateral side
followed by transendothelial transport and exocytosis at the
apical side, while apical-to-basolateral transport was undetect-
able (16). In the absence of significant brain-to-blood trans-
port of sAb, rapid clearance of sAb1–40 from the CSF, as re-
ported in rodents (43), could be important to maintaining low
concentrations of sAb in brain extracellular fluids. It is likely
that present in vitro findings could be extrapolated to humans
in vivo, since the in vivo evidence in rodents and nonhuman
primates confirms the net sAb1–40 BBB transport from blood-
to-brain (20–23, 44).
In addition to clearance, it is likely that brain metabolism
serves to maintain low levels of sAb in cerebrovascular and
brain interstitium to balance the effects of BBB transport of
circulating sAb and local brain production of peptide, which
both would tend to accumulate sAb in brain. In contrast to
metabolism of sAb1–40 in brain in vivo (22, 44), there was mini-
mal degradation of peptide by the HBMECs. The failure in
degradation mechanisms combined with an enhanced apical-
to-basolateral sAb transport, as in senescent squirrel monkey
(22), may enhance the development of cerebral amyloid angi-
opathy and increase sAb accumulation in brain. Whether this
same situation applies to BBB mechanisms in AD remains to
Figure 5. Interaction of SR with sAb1–40; studies on SR-transfected 
Bowes cells. (A) Dose-dependence of 125I-sAb1–40 binding. SR-trans-
fected Bowes cells were incubated with the indicated concentrations 
of 125I-sAb1–40 alone or in the presence of 100-fold excess of unlabeled 
ligand. Specific binding was determined and analyzed as described 
under Fig. 4 C. (B) Identification of surface-associated and internal-
ized 125I-sAb1–40. SR-transfected Bowes cells were either briefly 
treated with paraformaldehyde (fixed cells) or incubated in buffer 
alone (unfixed cells), followed by exposure to 125I-sAb1–40 as under 
Fig. 4 D. (C) Visualization of cell-associated sAb1–40. SR-transfected 
Bowes cells were incubated with sAb1–40 at 378C for 2 h. Cells were 
exposed to heparin containing buffer to elute surface bound Ab (CI), 
or were exposed to heparin followed by permeabilization with NP-40 
containing buffer (CII). Immunocytochemistry to visualize Ab was 
performed as described in the text.
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be elucidated. It has been suggested that Ab1–42 produced in
brain may favor amyloid “nucleation” (45) along with other
components, e.g., zinc and apoE, to accumulate soluble sAb1–40
from blood and CSF (1, 2, 46). At critical levels (47), and in the
presence of other predisposing factors (e.g., apoE4 genotype,
mutations in presenilin 1 and 2 genes, and mutations in amy-
loid-b protein precursor gene) (1) sAb may precipitate as
amyloid fibril in the vascular wall or in brain parenchyma,
could exert its cytotoxic effects (3–5) and contribute to neu-
ronal loss and the development of AD pathology (1).
Present findings support the vascular theory by demon-
strating that brain endothelial distribution of Ab receptors at
the apical side of the BBB could be responsible for interaction
of circulating sAb with the vessel wall, both for removal of this
peptide from plasma and possibly for inducing endothelial cell
injury (48, 49). The list of specific receptor- and/or carrier-
mediated BBB mechanism(s) participating in cerebrovascular
accumulation, deposition, and brain transfer of blood-borne
Ab1–40, the Dutch mutant vasculotropic peptide (AbQ) (22)
and Ab1–42 free or complexed with apoJ and apoE4 (21, 32,
38), and/or mediating vascular endothelial damage by Ab (3, 4,
48, 49) includes gp330/megalin, RAGE, SR, low- and high-
density lipoprotein receptors, vascular adhesion molecules, en-
doplasmic reticulum-associated Ab binding protein (35) and
possibly yet unidentified receptors/transporters.
The BBB permeability to Ab–apoJ complex via gp330/
megalin receptor was among the highest ever measured for
peptides/proteins at the BBB (38). The gp330/megalin at the
BBB works with the maximal transport capacity at physiologi-
cal plasma concentrations of apoJ (50), but despite its ex-
tremely high affinity for Ab–apoJ, this receptor does not trans-
port or bind free Ab at the BBB (38). The present study
reveals that RAGE and SR are responsible for BBB binding
of free Ab. Both the RAGE and SR are well known as recep-
tors with multiple functions including cellular endocytosis and
transcytosis of macromolecules (3, 51). Our studies support the
potential of RAGE and SR type A to interact with sAb1–40 me-
diating surface binding and, potentially, subsequent cellular
processing of the ligand. In terms of endocytosis of cell-bound
Ab, SR type A appears to be much more efficient than
RAGE. However, RAGE may function to pass off Ab to
other binding sites mediating passage through the endothelial
monolayer by mechanisms not adequately modeled in our
transfected cell system. Since the transfection studies were
performed in CHO and Bowes cells to examine separately the
contributions of RAGE and SR, respectively, rather than en-
dothelium, quantitative comparisons of the data are difficult to
make. Clearly, the crucial test of our hypothesis concerning re-
ceptor-dependent interactions of intravascular Ab will be in in
vivo studies using specific reagents to block contribution indi-
vidually of each receptor to cellular handling of Ab.
With respect to Ab BBB transcytosis, the present study
suggests the involvement of RAGE but also indicates a possi-
ble role for a RAGE-independent component that may be a
novel cytosolic Ab “chaperone” transporter protein. The mo-
lecular nature of this chaperone transporter protein remains to
be elucidated, as well as its functional relationship with
RAGE. It is possible that both RAGE and chaperone protein
exhibit similar kinetic affinities to transport Ab in the present
HBMEC model, so that Michealis–Menten analysis revealed a
single transport site. Alternatively, the affinity of one of these
components may be at the lower limit of sensitivity with the
present method, and molecular isolation and characterization
from cytosolic and cell membrane fractions should demon-
strate whether the transporter protein is different from known
Ab-binding proteins and/or receptors. The distribution of
cerebrovascular endothelial receptors for free and bound
forms of Ab in AD is unknown, but it is likely that they could
play important roles in Ab vascular binding and transport, and
therefore influence the development of cerebrovascular amy-
loidosis and vascular injury.
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